Osteoprotegerin (OPG) protects ovarian cancer cells from TRAIL-induced apoptosis but does not contribute to malignant ascites-mediated attenuation of TRAIL-induced apoptosis
© Lane et al.; licensee BioMed Central Ltd. 2012
Received: 6 September 2012
Accepted: 7 November 2012
Published: 15 November 2012
Resistance to apoptosis is a major problem in ovarian cancer and correlates with poor prognosis. Osteoprotegerin (OPG) is a secreted factor in malignant ascites and acts as a decoy receptor for receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). TRAIL promotes apoptosis in ovarian cancer cells. Ovarian cancer ascites attenuate TRAIL-induced apoptosis raising the possibility that OPG contained in ascites may abrogate the anti-tumor activity of TRAIL.
Determination of OPG levels in ascites was measured by ELISA. Effect of OPG on TRAIL-induced cell death was determined by XTT and colony forming assays in ovarian cancer cell lines and primary tumor cells. Apoptosis was assessed by ELISA.
We found that recombinant OPG and malignant ascites attenuates TRAIL-induced cell death and apoptosis in a dose-dependent manner in ovarian cancer cell lines and primary ovarian tumor cells. OPG is present at high levels in the ascites of patients with ovarian cancer. We found a positive correlation between the levels of OPG in ascites and the ability of the ascites to attenuate TRAIL-induced cell death. The anti-apoptotic effect of ascites was not reversed by co-incubation with an OPG blocking antibody.
OPG and malignant ascites protect ovarian cancer cells from TRAIL-induced apoptosis. Although malignant ascites contain high levels of OPG, OPG is not a critical component that contributes to ascites-mediated attenuation of TRAIL-induced apoptosis.
Ovarian cancer (OC) is the fifth cause of cancer-related death in women, the second most common gynecological cancer, and the leading cause of death from gynecological malignancies [1, 2]. Over 70% of patients with OC present with late stage disease, with dissemination of tumor implants throughout the peritoneal cavity [1–4]. Only 10-15% of these patients maintain complete response after standard first line treatments, implying that most patients will relapse. Indeed, the five-year survival of patients with late stage disease remains at < 30% with a median survival of 39 months . One of the main obstacles to effective treatment is the failure of initial therapy to eradicate a sufficient number of tumor cells to prevent disease recurrence.
One of the new promising anti-cancer therapies for OC is the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) . TRAIL is a member of the tumor necrosis factor family and has the ability to selectively induce apoptosis in tumor cells with little toxicity to normal cells. TRAIL has been shown to induce apoptosis in a wide range of tumor cells in vitro and in vivo, including OC cells [7–14]. TRAIL triggers apoptosis by interacting with TRAIL death receptors expressed by target cells. TRAIL binds to multiple receptors including TRAIL R1 (DR4), TRAIL R2 (DR5), TRAIL R3 (DcR1), TRAIL R4 (DcR2) [15–18]. Only TRAIL R1 and TRAIL R2 transmit an apoptotic signal. In contrast, TRAIL R3 and TRAIL R4 act as decoy receptors and are incapable of transmitting an apoptotic signal. Soluble TRAIL also binds with low affinity to soluble osteoprotegerin (OPG) . Binding of TRAIL to its death receptors allows the recruitment of Fas-associated protein with death domain (FADD) and pro-caspase 8/10 leading to the formation of the death-inducing signaling complex (DISC). In OC cells, activated caspase-8 cleaves pro-apoptotic Bcl-2 family member Bid to form truncated Bid (tBid), which can then interact with Bax/Bak leading to mitochondrial permeabilization and activation. This interaction increases the release of cytochrome c from the mitochondria resulting in the downstream activation of effector caspases .
OPG is a secreted member of the TNF receptor superfamily. It can bind to the receptor activator of NFκB ligand (RANKL) and functions as a soluble decoy receptor for RANKL. OPG regulates the homeostasis of bone remodeling by preventing RANKL from binding to its receptor RANK . OPG also acts as a decoy receptor of TRAIL and neutralizes its function . Several reports have shown that OPG is a survival factor and can block TRAIL-induced apoptosis in tumor cells. For example, human prostate cancer cells were shown to secrete OPG at concentrations sufficient to inhibit TRAIL-induced apoptosis in vitro [22, 23]. Similarly, multiple myeloma cells were protected from TRAIL-induced apoptosis by OPG produced from osteoblast-like cells and bone marrow stroma cells . OPG produced by breast cancer cells enhances tumor cell survival in vitro and in vivo by inhibiting TRAIL-induced apoptosis [25–28]. The production of OPG in colorectal cancer cells and the addition of exogenous OPG to colorectal cancer cells both caused resistance to TRAIL-induced apoptosis . The secretion of OPG in the bone microenvironment by either tumor cells or bone marrow stromal cells thus appears to be a critical survival factor for tumor cells. Furthermore, the production and release of OPG into the serum is higher in patients with late stage metastatic colon and prostate cancers suggesting that OPG might exert anti-apoptotic effect during the metastatic process [29, 30]. This is further supported by the observation that overexpression of OPG is associated with significantly worse overall survival and relapse-free survival in colon cancer patients . Moreover, overexpression of the OPG protein is an independent risk factor for colon cancer recurrence .
Recent data suggest that malignant ascites can affect tumor cell behavior by promoting cell growth, invasion, and survival [32–34]. Specifically, ascites from patients with advanced OC exert a protective effect against TRAIL- and drug-induced apoptosis by inducing survival pathways in tumor cells [32, 33, 35]. In addition, the presence of high levels of OPG in malignant ascites was recently associated with shorter progression-free survival in patients with OC . These observations raise the possibility that OPG may protect OC cells from TRAIL-induced apoptosis and that OPG production in malignant ascites may be a critical survival factor. In this study, we assessed whether recombinant OPG attenuates TRAIL-induced apoptosis in OC cell lines and primary tumor cells. In addition, we determined whether OPG in ascites facilitates survival of OC cells.
Malignant ascites, primary tumor cells and cell lines
The study was approved by the institutional review board of the Centre Hospitalier Universitaire de Sherbrooke. Informed consent was obtained from women that undergone surgery by the gynecologic oncology service for OC. Malignant ascites were obtained at the time of initial cytoreductive surgery for all patients. All ascites were supplied by the Banque de tissus et de données of the Réseau de Recherche en Cancer of the Fonds de la Recherche en Santé du Québec (FRSQ) affiliated with the Canadian Tumor Repository Network (CTRNet). Malignant ascites were centrifuged at 1000 rpm for 15 min and supernatants were stored at −20°C until assayed for protein content or XTT. Primary tumor cells were isolated as follow: ovarian cancer ascites were centrifuged at 1000 rpm for 15 min and cells were washed twice with OSE medium (Wisent, St-Bruno, Québec, Canada). Cells were then resuspended in OSE medium supplemented with 10% FBS, β-estradiol (10-8 M), 2 mM glutamine, antibiotics and fungizone and plated into 75 cm2 flasks. All floating cells were removed the next day. Tumor cell samples were used at low passage (< 10). All primary tumor cells were obtained from patients with advanced serous OC. To ensure that these cells were tumor cells, they were stained with epithelial tumor markers anti-CA125 and cytokeratine 8/18 and with fibroblast specific marker fibroblast antigen. As shown in Additional file 1: Figure S1, the human fibroblastic cell line HFL-1 (control) was positive for fibroblast antigen but negative for cytokeratine 8/18 as expected. In contrast, primary tumor cells OVC215A and OVC399A stained positive for cytokeratine 8/18 and CA125 and negative for fibroblast antigen, confirming that most cells are tumor cells. The OC cell lines CaOV3 and OVCAR3 were obtained from American Type Culture Collection, (Manassas, VA) and maintained in a humidified 5% CO2 incubator at 37°C. Cells were passaged twice weekly. OVCAR3 cells were maintained in RPMI-1640 (Wisent, St-Bruno, QC, Canada) supplemented with 20% FBS, insulin (10 mg/L), glutamine (2 mM) and antibiotics. CaOV3 cells were cultured in DMEM/F12 (Wisent) supplemented with 10% FBS, 2 mM glutamine and antibiotics.
Recombinant human TRAIL was purchased from PeproTech. (Rocky Hill, NJ). Recombinant human OPG and the anti-OPG neutralizing antibiody was purchased from R&D Systems (Mineapolis, MN). XTT reagent (2,3-bis-(2-methoxy-4-nitro-5-sulfo-phenyl)2H-tetrazolium-5-carboxonilide) was from Life Technology (Burlington, ON). The specific fibroblast antigen antibody was from Oncogen Research Product (clone AS02) (San Diego, CA). Anti-CA125 (M11) was from Dako (Burlington, ON) and anti-cytokeratine 8/18 antibody was from ZYMED laboratories Inc. (San Francisco, CA).
Cell viability assays
In some experiments cell viability was determined by XTT assay. Briefly, CaOV3 or OVCAR3 cells were plated at 20,000 cells/well in 96-well plates in complete medium. The next day, cells (confluence 60-70%) were exposed to medium containing OPG or ascites (10%) for 1 h after which TRAIL was added to the medium for total of 48 h. At the termination of the experiment, the culture media was removed and a mixture of PBS and fresh media (without phenol red) containing phenazine methosulfate and XTT was added for 30 min at room temperature. The O.D. was determined using a microplate reader at 450 nm (TecanSunrise, Research Triangle Park, NC). The percentage of cell viability was defined as the relative absorbance of TRAIL-treated cells versus untreated (no TRAIL, no ascites, no OPG) cells. Cells were also challenged with TRAIL in fresh medium supplemented with ascites (10%) and. To neutralize OPG in ascites, anti-OPG antibodies (10 μg/ml) were incubated for 1 h with ascites. The OPG-neutralized ascites were then added to cells and they were challenged with TRAIL for 48 h. In other experiments, cells were challenged with increasing concentration of TRAIL (0 to 50 ng/ml) in either fresh medium or medium containing ascites (10%) and the concentration of TRAIL allowing 50% cell viability was defined as the IC50. The anti-apoptotic activity of OC ascites was expressed as TRAIL IC50 with ascites/IC50 without ascites. Protective ascites were defined as those with a ratio ≥ 2.
For clonogenic survival assays, cells were plated into 25 mm2 tissue culture plates in standard medium. The next day, cells were incubated for 90 min in medium containing OPG (25 ng/ml) or ascites (10%) and TRAIL (50 ng/ml) was added to the medium for either 3 h or 48 h. Cells were then washed with PBS and incubated in fresh medium into 6-well plates at the different densities for 14 days. Cells were fixed and stained with crystal violet. The number of colonies, consisting of > 50 cells, in triplicate was counted.
Cells were incubated in medium containing OPG (25 ng/ml) for 1 h after which TRAIL (50 ng/m) was added to the medium and cells were incubated for 24 h. The release of nucleosomal DNA into the cytoplasm as a measure of apoptosis was determined using the Cell Death Detection ELISA Kit (Roche, Laval, Québec, Canada) according to the manufacturer’s instruction. The absorbance was determined using a microplate reader at 410 nm.
Determination of OPG concentration by ELISA
OPG levels were determined using an ELISA from E Biosciences (San Diego, CA). The assays were performed in duplicate according to the manufacturer’s protocols. The detection threshold was 4.5 pg/ml for OPG and the intra-assay variability was 4.3-7.9%.
Experiments were performed in triplicate, and data presented as mean ± SD. Student’s paired t-test was used to analyze differences between the treatment conditions and their controls. Dose responses were compared by ANOVA test. The threshold for statistical significance is P < 0.05.
OPG and malignant ascites protects OC cells from TRAIL-induced apoptosis
Presence of OPG in malignant ascites from patients with advanced OC
To assess whether OPG could be one of the determinants in ascites that contribute to ascites-mediated inhibition of TRAIL-induced apoptosis, we measured OPG by performing ELISA analysis of the acellular fraction of ascites obtained at the time of the initial surgery from 40 patients with OC (Additional file 2: Table S1). Most (70%) were serous sub-types and had advanced (stage III/IV) disease. ELISA analysis demonstrated that ascites contain OPG at very different levels (median 11.2 nM, range: 0.18-453 nM). This median OPG concentration in OC ascites (11.2 nM) is however lower than the apparent dissociation constant for the binding of OPG to TRAIL that is around 400 nM .
Ascites-mediated attenuation of TRAIL-induced apoptosis is OPG-independent
In this study, we tested the hypothesis that the anti-apoptotic effect of malignant ascites against TRAIL could be related to the presence of high levels of OPG. Previous studies have established that OPG acts as a survival factor, at least in vitro, by attenuating TRAIL-induced apoptosis in colon, breast and prostate cancer cells [22–29]. In addition, OPG appears to be a critical component of the bone microenvironment. Our in vitro results demonstrated that recombinant OPG protected CaOV3 and OVCAR3 cell lines from TRAIL-induced apoptosis in a dose-dependent manner. Furthermore, tumor cells isolated from malignant ascites were also protected from TRAIL-induced apoptosis by the addition of OPG, indicating that OPG acts as a survival factor for OC cells. Minimal concentrations of OPG required to significantly inhibit TRAIL-induced apoptosis in OC cell lines were in the order of 10 ng/ml. The level of OPG present in malignant ascites varied considerably between ascites and in many instances was too low (< 1 ng/ml) to counteract the apoptotic action of TRAIL. Nonetheless, we found a positive correlation between the level of OPG present in ascites and the ability of ascites to attenuate TRAIL-induced apoptosis. These observations may support the proposition that OPG, as an extracellular factor in malignant ascites, may function as a survival factor for OC cells.
The anti-apoptotic effect of recombinant OPG could be completely reversed by cotreatment with an anti-OPG blocking antibody whereas the antibody itself had no effect on apoptosis levels in OC cells (data not shown). CaOV3 cells treated with TRAIL in the presence of OVC508 and OVC551 ascites containing 3.6 ng/ml and 19,6 ng/ml respectively of OPG showed lower level of cell death compared to those treated with TRAIL alone. Although this anti-apoptotic effect of ascites was hypothesized to be due, at least in part, to the presence of OPG, incubation of CaOV3 cells with the OPG blocking antibody had no effect on the anti-apoptotic property of OVC508 and OVC551, suggesting that OPG is not a critical survival factor in ascites.
The source of OPG in malignant ascites remains to be established but it has been shown that a number of different cell types are capable of producing OPG. Data from other studies suggest that prostate and breast cancer cells can produce OPG [22, 23, 25–28]. Our data demonstrated that OC cancer cell lines and primary tumor cells isolated from ascites also produce OPG with concentration ranging from 30 to 1031 pg/ml. These concentrations were well within the range of those found in malignant ascites. The overall contribution of the various cell populations to the total OPG levels in ascites will depend on the number of tumor cells in relation to other cells. Stromal cells have been shown to be a significant source of OPG [25, 37]. In this context, it could be speculated that, in addition to tumor cells, human peritoneal mesothelial cells, which are an important constituent of malignant ascites, could also be a source of OPG.
In summary, although most malignant ascites have measurable OPG level, these concentrations do not reach the level required to attenuate TRAIL-induced apoptosis in the majority of ascites. In addition, blockade of endogenous OPG in ascites do not affect their anti-apoptotic activity. Thus, the presence of OPG in malignant ascites by itself is an unlikely mechanism by which ascites attenuate TRAIL-induced apoptosis.
This work was supported by fundings from the Cancer Research Society and the Canadian Institutes of Health Research (MOP – 115072) (A.P.). We wish to thank the Banque de tissus et de données du Réseau de Recherche en Cancer des Fonds de la Recherche en Santé du Québec (FRSQ), affiliated to the Canadian Tumor Repository Network (CTRNet) for providing the ascites samples.
- Partridge EE, Barnes MN: Epithelial ovarian cancer: prevention, diagnosis, and treatment. CA Cancer J Clin 1999, 49: 297–320. 10.3322/canjclin.49.5.297PubMedView ArticleGoogle Scholar
- Goff BA, Mandel L, Muntz HG, Melancon CH: Ovarian carcinoma diagnosis. Cancer 2000, 89: 2068–2075. 10.1002/1097-0142(20001115)89:10<2068::AID-CNCR6>3.0.CO;2-ZPubMedView ArticleGoogle Scholar
- Ozols RF, Bookman MA, Connolly DC, Daly MB, Godwin AK, Schilder RJ, Xu X, Hamilton TC: Focus on epithelial ovarian cancer. Cancer Cell 2004, 5: 19–24. 10.1016/S1535-6108(04)00002-9PubMedView ArticleGoogle Scholar
- Aletti GD, Gallenberg MM, Cliby WA, Jatoi A, Hartmann LC: Current management strategies for ovarian cancer. Mayo Clin Proc 2007, 82: 751–770.PubMedView ArticleGoogle Scholar
- Herzog TJ: Recurrent ovarian cancer: how important is it to treat to disease progression? Clin Cancer Res 2004, 10: 7439–7449. 10.1158/1078-0432.CCR-04-0683PubMedView ArticleGoogle Scholar
- Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A: Targeted ovarian cancer treatment: the TRAILs of resistance. Am J Cancer Res 2012, 2: 75–92.Google Scholar
- Lane D, Cartier A, L’Espérance S, Côté M, Rancourt C, Piché A: Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol Oncol 2004, 93: 594–604. 10.1016/j.ygyno.2004.03.029PubMedView ArticleGoogle Scholar
- Cuello M, Ettenberg SA, Nau MM, Lipkowitz S: Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol Oncol 2001, 81: 380–390. 10.1006/gyno.2001.6194PubMedView ArticleGoogle Scholar
- Vignati S, Codegoni A, Polato F, Broggini M: TRAIL activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur J Cancer 2002, 38: 177–183. 10.1016/S0959-8049(01)00345-8PubMedView ArticleGoogle Scholar
- Siervo-Sassi RR, Marrangoni AM, Feng X, Naoumova N, Winans M, Edwards RP, Lokshin A: Physiological and molecular effects of Apo2L/TRAIL and cisplatin in ovarian carcinoma cell lines. Cancer Lett 2003, 190: 61–72. 10.1016/S0304-3835(02)00579-7PubMedView ArticleGoogle Scholar
- Tomek S, Horak P, Pribill I, Haller G, Rössler M, Zielinski CC, Pils D, Krainer M: Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs. Gynecol Oncol 2004, 94: 107–114. 10.1016/j.ygyno.2004.04.012PubMedView ArticleGoogle Scholar
- Liu P, Mao H, Hou P: Synergistic antitumor effect of tumor necrosis factor-related apoptosis-inducing ligand combined with cisplatin in ovarian carcinoma cell lines in vitro and in vivo. Int J Gynecol Cancer 2006, 16: 538–548.PubMedView ArticleGoogle Scholar
- Estes JM, Oliver PG, Straughn JM Jr, Zhou T, Wang W, Grizzle WE, Alvarez RD, Stockard CR, LoBuglio AF, Buchsbaum DJ: Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model. Gynecol Oncol 2007, 105: 291–298. 10.1016/j.ygyno.2006.12.033PubMedView ArticleGoogle Scholar
- Bevis KS, McNally LR, Sellers JC, Della Manna D, Londoño Joshi A, Amm H, Straughn JM Jr, Buchsbaum DJ: Anti-tumor activity of an anti-DR5 monoclonal antibody, TRA-8, in combination with taxane/platinum-based chemotherapy in an ovarian cancer model. Gynecol Oncol 2011, 121: 193–199. 10.1016/j.ygyno.2010.11.046PubMedView ArticleGoogle Scholar
- Pan G, O’Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, Dixit VM: The receptor for the cytotoxic ligand TRAIL. Science 1997, 276: 111–113. 10.1126/science.276.5309.111PubMedView ArticleGoogle Scholar
- Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM: An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997, 277: 815–818. 10.1126/science.277.5327.815PubMedView ArticleGoogle Scholar
- Sheridan JP, Marsters SA, Pitti RM, Gurney A, Skubatch M, Baldwin D, Ramakrishnan L, Gray CL, Baker K, Wood WI, Goddard AD, Godowski P, Ashkenazi A: Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997, 277: 818–821. 10.1126/science.277.5327.818PubMedView ArticleGoogle Scholar
- Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, Yuan J, Gurney A, Goddard AD, Godowski P, Ashkenazi A: A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997, 7: 1003–1006. 10.1016/S0960-9822(06)00422-2PubMedView ArticleGoogle Scholar
- Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998, 273: 14363–14367. 10.1074/jbc.273.23.14363PubMedView ArticleGoogle Scholar
- Goncharenko-Khaider N, Lane D, Matte I, Rancourt C, Piché A: The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced apoptosis in ovarian cancer cells. Oncogene 2010, 29: 5523–5536. 10.1038/onc.2010.288PubMed CentralPubMedView ArticleGoogle Scholar
- Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ: Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 1997, 89: 309–319. 10.1016/S0092-8674(00)80209-3PubMedView ArticleGoogle Scholar
- Holen I, Croucher PI, Hamdy FC, Eaton CL: Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 2002, 62: 1619–1623.PubMedGoogle Scholar
- Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL: Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 2005, 65: 1710–1718. 10.1158/0008-5472.CAN-04-2033PubMedView ArticleGoogle Scholar
- Shipman CM, Croucher PI: Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 2003, 63: 912–916.PubMedGoogle Scholar
- Neville-Webbe HL, Cross NA, Eaton CL, Nyambo R, Evans CA, Coleman RE, Holen I: Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat 2004, 86: 269–279.PubMedView ArticleGoogle Scholar
- Holen I, Cross SS, Neville-Webbe HL, Cross NA, Balasubramanian SP, Croucher PI, Evans CA, Lippitt JM, Coleman RE, Eaton CL: Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo – a role in tumour cell survival? Breast Cancer Res Treat 2005, 92: 207–215. 10.1007/s10549-005-2419-8PubMedView ArticleGoogle Scholar
- Fisher JL, Thomas-Mudge RJ, Elliott J, Hards DK, Sims NA, Slavin J, Martin TJ, Gillespie MT: Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 2006, 66: 3620–3628. 10.1158/0008-5472.CAN-05-3119PubMedView ArticleGoogle Scholar
- Rachner TD, Benad P, Rauner M, Goettsch C, Singh SK, Schoppet M, Hofbauer LC: Osteoprotegerin production by breast cancer cells is suppressed by dexamethasone and confers resistance against TRAIL-induced apoptosis. J Cell Biochem 2009, 108: 106–116. 10.1002/jcb.22232PubMedView ArticleGoogle Scholar
- De Toni EN, Thieme SE, Herbst A, Behrens A, Stieber P, Jung A, Blum H, Göke B, Kolligs FT: OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res 2008, 14: 4713–4718. 10.1158/1078-0432.CCR-07-5019PubMedView ArticleGoogle Scholar
- Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, Rabbani SA: Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 2006, 107: 289–298. 10.1002/cncr.21978PubMedView ArticleGoogle Scholar
- Tsukamoto S, Ishikawa T, Iida S, Ishiguro M, Mogushi K, Mizushima H, Uetake H, Tanaka H, Sugihara K: Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res 2011, 17: 2444–2450. 10.1158/1078-0432.CCR-10-2884PubMedView ArticleGoogle Scholar
- Lane D, Robert V, Grondin R, Rancourt C, Piché A: Malignant ascites protect against TRAIL-induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells. Int J Cancer 2007, 121: 1227–1237. 10.1002/ijc.22840PubMedView ArticleGoogle Scholar
- Lane D, Goncharenko-Khaider N, Rancourt C, Piché A: Ovarian cancer ascites protects from TRAIL-induced cell death through αvβ5 integrin-mediated focal adhesion kinase and Akt activation. Oncogene 2010, 29: 3519–3531. 10.1038/onc.2010.107PubMedView ArticleGoogle Scholar
- Puiffe ML, Le Page C, Filali-Mouhim A, Zietarska M, Ouellet V, Tonin PN, Chevrette M, Provencher DM, Mes-Masson AM: Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia 2007, 9: 820–829. 10.1593/neo.07472PubMed CentralPubMedView ArticleGoogle Scholar
- Lane D, Matte I, Rancourt C, Piché A: The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer. J Ovarian Res 2010, 3: 1. 10.1186/1757-2215-3-1PubMed CentralPubMedView ArticleGoogle Scholar
- Matte I, Lane D, Laplante C, Rancourt C, Piché A: Profiling of cytokines in human epithelial ovarian cancer ascites. Am J Cancer Res 2012, 2: 566–580.PubMed CentralPubMedGoogle Scholar
- Lu TY, Kao CF, Lin CT, Huang DY, Chiu CY, Huang YS, Wu HC: DNA methylation and histone modification regulate silencing of OPG during tumor progression. J Cell Biochem 2009, 108: 315–325. 10.1002/jcb.22256PubMedView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.